Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC
NCT06228924
This study is recruiting at 7 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
This first-in-human study is designed to evaluate the safety, and preliminary efficacy (PD) of TN-401 gene therapy in adult patients with symptomatic PKP2 mutation-associated ARVC.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Arrhythmogenic Right Ventricular Cardiomyopathy
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Tenaya Therapeutics
- Last updated on ClinicalTrials.gov
- February 6, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California San Francisco · San Francisco, CA
Colorado · 1
- University of Colorado - Anschutz Medical Campus · Aurora, CO
Maryland · 1
- Johns Hopkins University · Baltimore, MD
Massachusetts · 1
- Brigham and Women's Hospital · Boston, MA
Minnesota · 1
- Mayo Clinic · Rochester, MN
New York · 1
- NYU Langone Health · New York, NY
Ohio · 1
- Cleveland Clinic · Cleveland, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.